Primary Myelofibrosis

Shaping your forecasting.

Welcome to theHub

Primary Myelofibrosis

Primary Myelofibrosis (PMF), also known as myelofibrosis, myeloid metaplasia or chronic idiopathic myelofibrosis, is part of the collection of diseases known as myeloproliferative neoplasms (MPNs).

Read More about Primary Myelofibrosis

PMF is a chronic blood cancer that affects the haematopoietic system, causing progressive fibrosis of the marrow and impairs the ability of new blood cell production. Eventually, the marrow is unable to produce blood cells, and the spleen and liver take over the function causing abdominal swelling and discomfort. Main symptoms and co-morbidities for PMF include:

Portal hypertension
Thrombosis
Anaemia
Gout
Extramedullary haematopoiesis
Leukocytosis
Splenomegaly
Acute myeloid leukaemia

Epidemiology Data

Data Available: Prevalence Data

Data covers: Males and Females (where applicable) from 2010 to 2050.

Data is split into 5 year age ranges (0-4, 5-9 etc) from 0 to 100+ years, across multiple countries.

Additional sub filters of the data are available. Please see the below pop up box for more information.

Once purchased, the data will be provided in an embedded PowerBI document, in which the data can be filtered and viewed in a way which suits your needs. Raw data can also be downloaded. Below is an example embedded data set which can be filtered in a similar way.

Instructions:
Once the data set has been purchased, please refresh this page. The example data set will then be replaced with actual data.

Please contact us for further information regarding filtering of the data, viewing the data, data available, custom quotes, or anything else.

Read More about the Data Filters available within the Epi Data

As well as prevalence, data can be filtered by the following attributes :

• marrow staging
• Circulating blasts (%)
• Dupriez score
• Haemoglobin (g/dL)
• Hepatomegaly Absent
• Hepatomegaly Present
• Immature granulocytes(%)
• Incident Thrombosis
• IPSS Risk Category
• JAK2-V617F Mutation
• Platelet count (x10^9/L)
• Portal hypertension
• Progression to acute myelogenous leukaemia
• Reticulocytes (x10^9/L)
• Spleen involvement
• Thrombotic event history
• White blood cell count (x10^9/dL)

Further sub sets are available within the data. Please contact us for more information.

Countries Covered

Argentina
Australia
Brazil
Canada
China
France
Germany
India
Italy
Japan
Mexico
Netherlands
Poland
Republic of Korea
Russian Federation
Spain
Turkey
United Kingdom
United States of America

The more you buy, the more you save*

View cart

*discount added at checkout

For all your pharmaceutical
forecasting needs.

theHub is a portal of resources to help you create better forecasting. Courses, templates, software, data and working model examples to get you on the path to better forecasting. Sign up now to get access to a world of interactive content.

About J+D Forecasting.

At J+D it's our mission to simplify the complex nature of pharmaceutical forecasting to help support informed decision making for the future. We are dedicated to helping pharmaceutical and biotech companies use intelligent forecasting solutions to make strategic and operational investment decisions.

For decades, we have crafted bespoke pharmaceutical forecasting models, innovative software and interactive training solutions, each of which has been designed with client needs in mind, allowing businesses to create more intelligent and consistent insights.